Pharmaceuticals, Biotechnology and Life Sciences
NBI-1117568 is an oral, muscarinic M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration…
Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatmentof Focal Segmental Glomerulosclerosis (FSGS) DMX-200 is in a pivotal…
Tokyo, Japan and Cambridge, UK, 1 May 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today…
Cincinnati, OH, April 30, 2025 (GLOBE NEWSWIRE) — Onconetix, Inc. (Nasdaq: ONCO) (the “Company”) announced that it received a Staff…
SAN ANTONIO, April 30, 2025 (GLOBE NEWSWIRE) — Scorpius Holdings, Inc (OTC: SCPX) (“Scorpius” or “the Company”), an integrated contract…
REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing…
FOSTER CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage…
REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for…
SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) — Vaxart, Inc. (NASDAQ: VXRT) today announced that members of the management…
CEA-targeted ISAC elicits complete responses in mice and is well-tolerated in NHPs PD-L1 ISAC directly activates and reprograms PD-L1-expressing myeloid…